STSA - Satsuma randomizes first subject in late-stage STS101 migraine study

Satsuma Pharmaceuticals (STSA) announces randomization of the first subject in its SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine.The trial of STS101 is a multi-center, single-dose, randomized, double-blind, placebo-controlled, parallel group study in about 1,400 subjects with migraine that is being conducted in the United States.The co-primary endpoints of the trial, to be assessed at two hours after STS101 administration, are freedom from pain and freedom from most bothersome symptom (from among photophobia, phonophobia or nausea).Satsuma expects to report top-line data from the SUMMIT trial in the second half of 2022.Shares up more than 6% post market.

For further details see:

Satsuma randomizes first subject in late-stage STS101 migraine study